{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T17:40:31Z","timestamp":1719164431747},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,23]]},"DOI":"10.7759\/cureus.62975","type":"journal-article","created":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T17:25:05Z","timestamp":1719163505000},"source":"Crossref","is-referenced-by-count":0,"title":["Navigating the Nexus: Lenalidomide-Associated Thrombotic Thrombocytopenic Purpura"],"prefix":"10.7759","author":[{"given":"Ghida","family":"Akhdar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inemesit","family":"Akpan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1611423","article-title":"An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura","volume":"12","author":"Joly BS","year":"2019","unstructured":"Joly BS, Coppo P, Veyradier A. An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Rev Hematol. 2019, 12:383-95. 10.1080\/17474086.2019.1611423","journal-title":"Expert Rev Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2016.09.010","article-title":"Syndromes of thrombotic microangiopathy","volume":"101","author":"Shatzel JJ","year":"2017","unstructured":"Shatzel JJ, Taylor JA. Syndromes of thrombotic microangiopathy. Med Clin North Am. 2017, 101:395-415. 10.1016\/j.mcna.2016.09.010","journal-title":"Med Clin North Am"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16333","article-title":"Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature","volume":"188","author":"Elessa D","year":"2020","unstructured":"Elessa D, Talbot A, Lombion N, et al.. Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature. Br J Haematol. 2020, 188:338-40. 10.1111\/bjh.16333","journal-title":"Br J Haematol"},{"key":"ref4","article-title":"Thrombotic thrombocytopenic purpura: report of three additional cases and a short review of the literature","volume":"62","author":"Cox EC","year":"1966","unstructured":"Cox EC. Thrombotic thrombocytopenic purpura: report of three additional cases and a short review of the literature. J S C Med Assoc. 1966, 62:465-70.","journal-title":"J S C Med Assoc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-196603000-00003","article-title":"Thrombotic thrombocytopenic purport: report of 16 cases and review of the literature","volume":"45","author":"Amorosi EL","year":"1966","unstructured":"Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purport: report of 16 cases and review of the literature. Medicine. 1966, 45:139-60. 10.1097\/00005792-196603000-00003","journal-title":"Medicine"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/638020","article-title":"Lenalidomide-associated ITP","volume":"2011","author":"Herold CI","year":"2011","unstructured":"Herold CI, Gasparetto C, Arepally GM. Lenalidomide-associated ITP. Case Rep Hematol. 2011, 2011:638020. 10.1155\/2011\/638020","journal-title":"Case Rep Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24447","article-title":"Proteasome inhibitor associated thrombotic microangiopathy","volume":"91","author":"Yui JC","year":"2016","unstructured":"Yui JC, Van Keer J, Weiss BM, et al.. Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol. 2016, 91:E348-52. 10.1002\/ajh.24447","journal-title":"Am J Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24662","article-title":"Ixazomib-induced thrombotic microangiopathy","volume":"92","author":"Yui JC","year":"2017","unstructured":"Yui JC, Dispenzieri A, Leung N. Ixazomib-induced thrombotic microangiopathy. Am J Hematol. 2017, 92:E53-5. 10.1002\/ajh.24662","journal-title":"Am J Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfv059","article-title":"Thrombotic microangiopathy associated with proteasome inhibitors","volume":"8","author":"Lodhi A","year":"2015","unstructured":"Lodhi A, Kumar A, Saqlain MU, Suneja M. Thrombotic microangiopathy associated with proteasome inhibitors. Clin Kidney J. 2015, 8:632-6. 10.1093\/ckj\/sfv059","journal-title":"Clin Kidney J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.1214","article-title":"Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment","volume":"5","author":"Gosain R","year":"2017","unstructured":"Gosain R, Gill A, Fuqua J, et al.. Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment. Clin Case Rep. 2017, 5:1926-30. 10.1002\/ccr3.1214","journal-title":"Clin Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2008.08.003","article-title":"The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions","volume":"77","author":"Lu L","year":"2009","unstructured":"Lu L, Payvandi F, Wu L, et al.. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009, 77:78-86. 10.1016\/j.mvr.2008.08.003","journal-title":"Microvasc Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina V","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, et al.. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008, 358:1129-36. 10.1056\/NEJMoa0707330","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.12.52","article-title":"Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis","volume":"5","author":"Boyle EM","year":"2012","unstructured":"Boyle EM, Fouquet G, Manier S, et al.. Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis. Expert Rev Hematol. 2012, 5:617-26. 10.1586\/ehm.12.52","journal-title":"Expert Rev Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo P","year":"2010","unstructured":"Coppo P, Schwarzinger M, Buffet M, et al.. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One. 2010, 5:e10208. 10.1371\/journal.pone.0010208","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.914203","article-title":"Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide","volume":"55","author":"Montefusco V","year":"2014","unstructured":"Montefusco V, Galli M, Spina F, et al.. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide. Leuk Lymphoma. 2014, 55:2032-7. 10.3109\/10428194.2014.914203","journal-title":"Leuk Lymphoma"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2421-0","article-title":"Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma","volume":"94","author":"Cheah CY","year":"2015","unstructured":"Cheah CY, Orlowski RZ, Manasanch EE, Oo TH. Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma. Ann Hematol. 2015, 94:1605-7. 10.1007\/s00277-015-2421-0","journal-title":"Ann Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4927.4927","article-title":"Four cases of lenalidomide-associated immune thrombocytopenia","volume":"128","author":"Pompa A","year":"2016","unstructured":"Pompa A, Guidotti F, Gregorini AI, et al.. Four cases of lenalidomide-associated immune thrombocytopenia. Blood. 2016, 128:4927. 10.1182\/blood.V128.22.4927.4927","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8825618","article-title":"Lenalidomide-associated immune thrombocytopenia: a case report and review of the literature","volume":"2020","author":"Forehand W","year":"2020","unstructured":"Forehand W, Ajebo G, Toscano M, Jillella A, Dainer P. Lenalidomide-associated immune thrombocytopenia: a case report and review of the literature. Case Rep Hematol. 2020, 2020:8825618. 10.1155\/2020\/8825618","journal-title":"Case Rep Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/266735-navigating-the-nexus-lenalidomide-associated-thrombotic-thrombocytopenic-purpura","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T17:25:10Z","timestamp":1719163510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/266735-navigating-the-nexus-lenalidomide-associated-thrombotic-thrombocytopenic-purpura"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,23]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.62975","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,23]]}}}